Topics:

EU signs off on Lilly's Alzheimer's imaging agent

Tools

While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe. Lilly ($LLY) announced today that EU regulators have approved Amyvid with PET imaging for use in adult patients who are being evaluated for Alzheimer's disease and other cognitive conditions. The tool measures the level of plaque in the brain, which is associated with Alzheimer's. Report